by GlobeNewsWire | Sep 12, 2016 | Globe Newswire
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced results from the Company’s Phase 1A study in healthy volunteers evaluating oral non-covalent BTK inhibitor SNS-062. The study demonstrated...
by GlobeNewsWire | Sep 7, 2016 | Globe Newswire
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-6 reverse stock...
by GlobeNewsWire | May 25, 2016 | Globe Newswire
Sunesis Provides Educational Grant to Support Campaign Sponsor CancerCare SOUTH SAN FRANCISCO, Calif., May 25, 2016 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced its support for the first-ever Acute Myeloid Leukemia Awareness...
by GlobeNewsWire | May 18, 2016 | Globe Newswire
SOUTH SAN FRANCISCO, Calif., May 18, 2016 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at the 2016 UBS Global Healthcare Conference on Wednesday, May 25th at...
by GlobeNewsWire | Apr 1, 2016 | Globe Newswire
SOUTH SAN FRANCISCO, Calif., April 01, 2016 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has entered into a $15 million loan agreement (“the agreement”) with Bridge Bank, a division of Western Alliance Bank and Solar...